Cargando…
Circulating biomarkers and cardiac function over 3 years after chemotherapy with anthracyclines: the ICOS‐ONE trial
AIMS: A multicentre trial, ICOS‐ONE, showed increases above the upper limit of normality of cardiac troponin (cTn) in 27% of patients within 12 months after the end of cancer chemotherapy (CT) with anthracyclines, whether cardiac protection with enalapril was started at study entry in all (preventio...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7373944/ https://www.ncbi.nlm.nih.gov/pubmed/32358917 http://dx.doi.org/10.1002/ehf2.12695 |